NEWS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Immune Design to Present at 3rd Annual Cancer Immunotherapy Conference
Immune Design to Present at 3rd Annual Cancer Immunotherapy Conference SEATTLE, Oct. 2, 2012 (GLOBE NEWSWIRE) -- Immune Design today announced that the company will be presenting at the 3 rd Annual Cancer Immunotherapy: A Long-Awaited Reality conference on Thursday, October 4, at 3:15 p.m.
View HTML
Toggle Summary Immune Design Corp. Announces Appointment of Dr. Roger Perlmutter as a Member of Its Board of Directors
Immune Design Corp. Announces Appointment of Dr. Roger Perlmutter as a Member of Its Board of Directors SEATTLE, June 26, 2012 (GLOBE NEWSWIRE) -- Immune Design Corp. announced today the appointment of Roger M. Perlmutter, M.D., Ph.D., as a member of its Board of Directors. Dr.
View HTML
Toggle Summary Immune Design Corp. Appoints Wayne R. Gombotz, Ph.D. as Chief Development Officer
Immune Design Corp. Appoints Wayne R. Gombotz, Ph.D. as Chief Development Officer SEATTLE , Dec. 2, 2011 /PRNewswire/ -- Immune Design Corp. announced today that Wayne R. Gombotz , Ph.D. has joined the company as its new Chief Development Officer.  Dr.
View HTML
Toggle Summary Immune Design Corp. and Sanofi-Aventis Announce Research Collaboration
Immune Design Corp. and Sanofi-Aventis Announce Research Collaboration SEATTLE , Oct. 26, 2011 /PRNewswire/ -- Immune Design Corp. (IDC), a privately held biotechnology company developing novel vaccines and immunotherapies for infectious disease, cancer and allergy, announced today that it has
View HTML
Toggle Summary Immune Design Corp. Appoints Pharma and Biotech Executive Carlos V. Paya, MD, PhD as Chief Executive Officer
Immune Design Corp. Appoints Pharma and Biotech Executive Carlos V. Paya, MD, PhD as Chief Executive Officer SEATTLE , April 27, 2011 /PRNewswire/ -- Immune Design Corp. (IDC) announced today that Carlos V. Paya , MD, PhD, will join IDC as Chief Executive Officer and Board Director effective May 2,
View HTML
Toggle Summary Immune Design Grants Adjuvant License to MedImmune
Immune Design Grants Adjuvant License to MedImmune SEATTLE , Oct. 26 /PRNewswire/ -- Immune Design Corp. (IDC), a privately held biotechnology company developing novel vaccines and immunotherapies for infectious disease and cancer, announced today that it has entered into a license and development
View HTML
Toggle Summary Immune Design Corp. Raises $32 Million in Series B Financing
Immune Design Corp. Raises $32 Million in Series B Financing SEATTLE , July 26 /PRNewswire/ -- Immune Design Corp. (IDC), a privately held biotechnology company focused on developing novel vaccines and immunotherapies for infectious disease and cancer, announced today that it has secured $32
View HTML
Toggle Summary Immune Design Corp. Announces Appointment of Dr. Bruce L.A. Carter as Executive Chairman and Director
Immune Design Corp. Announces Appointment of Dr. Bruce L.A. Carter as Executive Chairman and Director SEATTLE, Nov. 23 /PRNewswire/ -- Immune Design Corp. (IDC) announced today that Dr. Bruce L.A. Carter has joined IDC as Executive Chairman. Dr. Carter has a successful track record in biotechnology
View HTML